BioCentury | Oct 28, 2020
Deals

In third cancer deal, EQRx aims to bring down cost of PD-1, PD-L1 inhibitors

Through its latest deal with CStone, EQRx is looking to bring lower cost PD-1 and PD-L1 inhibitors to market. EQRx Inc. launched in January with a $200 million series A and a mission to bring innovative...
BioCentury | Sep 19, 2020
Translation in Brief

Gene therapies from Passage Bio, Locanabio; Lava’s antitumor bispecific, health disparities in Alzheimer’s and more

Passage Bio’s frontotemporal dementia gene therapyUniversity of Pennsylvania spinout Passage Bio Inc. reported that administration of PBFT02, an AAV1-GRN vector, led to elevated levels of PGRN in the brain and cerebral spinal fluid (CSF), reduced lysosomal...
BioCentury | Sep 18, 2020
Finance

Lava’s $83M series C exemplifies evolution of Novo Ventures’ investing

...this week that detailed how a bispecific targeting CD1D could activate both Vγ9Vδ2 T cells and natural killer T cells. “You...
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

Fibrosis company Avalyn raises $35.5M series B Seattle’s Avalyn Pharma Inc. closed a $35.5 million B round, adding to its $62 million series A in 2017. The round was led by Norwest Venture Partners with...
BioCentury | Feb 28, 2020
Emerging Company Profile

Lava: better safety for bispecifics with γδ T cell engagement

Lava’s bispecific mAbs targeting γδ T cells could match the potency of other T cell engaging technologies while offering a larger therapeutic window. The company joins a growing group of biotechs focused on γδ T...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Feb 28, 2019
Financial News

CStone raises $285M in Hong Kong IPO

CStone Pharmaceuticals Co. Ltd. (HKSE:2616) priced its IPO on the Hong Kong stock exchange Feb. 25, raising HK$2.2 billion (US$285 million). The oncology company rose HK$0.86 to HK$12.86 in its first day of trading Feb....
BioCentury | Feb 26, 2019
Financial News

First-day gain for CStone on Hong Kong exchange

CStone Pharmaceuticals Co. Ltd. (HKSE:2616) rose HK$0.86 to HK$12.86 in its first day of trading Tuesday after raising HK$2.2 billion ($285 million) in its IPO. The oncology company priced the offering early Monday near the...
BioCentury | Feb 25, 2019
Financial News

CStone raises $285M in Hong Kong IPO

CStone Pharmaceuticals Co. Ltd. (HKSE:2616) priced its IPO on the Hong Kong stock exchange early Monday, raising HK$2.2 billion (US$285 million). The offering values CStone at HK$11.8 billion (US$1.5 billion). CStone sold 18.6 million shares...
BioCentury | Feb 15, 2019
Financial News

CStone could get $1.5B valuation in Hong Kong IPO

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) would be valued at HK$11.8 billion ($1.5 billion) if it prices its Hong Kong IPO at the midpoint of its proposed range. The cancer company plans to sell 186.4...
Items per page:
1 - 10 of 156